https://scholars.lib.ntu.edu.tw/handle/123456789/638270
標題: | Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria | 作者: | Huang, Chian Tzu Chu, Yu Long TUNG-HUNG SU SHANG-CHIN HUANG TAI-CHUNG TSENG SHIH-JER HSU SIH-HAN LIAO CHUN-MING HONG CHEN-HUA LIU HUNG-CHIH YANG CHUN-JEN LIU PEI-JER CHEN JIA-HORNG KAO |
關鍵字: | Barcelona Clinic Liver Cancer | Overall survival | Surgical resection | Transarterial chemoembolization | Tumor burden | Up-To-7 criteria | 公開日期: | 19-十二月-2023 | 卷: | 12 | 期: | 6 | 來源出版物: | Liver Cancer | 摘要: | Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC)-A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened, and those who received transarterial chemoembolization (TACE) or SR were consecutively included. The tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7-11), or high (>11). Multivariable Cox proportional hazard regression analysis was used for outcome prediction. Results: Overall, 474 patients who received SR (n = 247) and TACE (n = 227) were enrolled. Patients who underwent SR were significantly younger with better liver reserve. There were 76 (31%) and 129 (57%) deaths in the SR and TACE groups after a median follow-up of 3.9 and 2.1 years, respectively. The seven-eleven criteria could distinguish median overall survival (OS) among low (n = 149), intermediate (n = 203), and high (n = 122) tumor burden groups (7.7 vs. 6.9 vs. 2.8 years, respectively, p < 0.001). Patients receiving SR had a significantly higher median OS compared with TACE in those with intermediate (8.2 vs. 2.6 years, p < 0.001) and high (5.6 vs. 1.5 years, p = 0.001) tumor burden. After adjustment for age, sex, and liver reserve, SR was predictive for better OS in intermediate (adjusted hazard ratio [aHR]: 0.45, 95% confidence interval [CI]: 0.27-0.75) and high tumor burden groups (aHR: 0.54, 95% CI: 0.32-0.92). The survival benefit of SR especially confines to patients within 3 tumors. Conclusions: In patients with BCLC-A/B HCC beyond the Milan criteria with tumor burden beyond the up-To-7 criteria but within 3 tumors, SR has better OS than TACE and should be considered in resectable patients. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638270 | ISSN: | 22351795 | DOI: | 10.1159/000529143 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。